The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.
This week on Pipeline Moves, we kick off by looking at Pfizer’s topline data from a Phase II trial of ponsegromab on cancer ...
4d
Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...
Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.
Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...
U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where ...
Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...
Pfizer had big hopes for a sickle-cell disease drug, as did those suffering from the disease. Things didn't turn out as ...
Pfizer remains an attractive capital return play with a 10X P/E ratio, despite concerns about post-COVID revenue declines.
Pfizer will voluntarily pull its sickle cell disease (SCD) drug Oxbryta from all markets worldwide, a major blow to a $5.4 ...
We recently published a list of Jim Cramer’s Latest Portfolio: Top 9 Stocks to Buy and Sell. Since Pfizer Inc. (NYSE:PFE) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback